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The epidemiology of vancomycin-resistant Entero-
coccus faecium (VREF) in Europe is characterized by a
large community reservoir. In contrast, nosocomial out-
breaks and infections (without a community reservoir) char-
acterize VREF in the United States. Previous studies
demonstrated host-specific genogroups and a distinct
genetic lineage of VREF associated with hospital out-
breaks, characterized by the variant esp-gene and a specif-
ic allele-type of the purK housekeeping gene (purK1). We
investigated the genetic relatedness of vanA VREF
(n=108) and vancomycin-susceptible E. faecium (VSEF)
(n=92) from different epidemiologic sources by genotyping,
susceptibility testing for ampicillin, sequencing of purK1,
and testing for presence of esp. Clusters of VSEF fit well
into previously described VREF genogroups, and strong
associations were found between VSEF and VREF isolates
with resistance to ampicillin, presence of esp, and purK1.
Genotypes characterized by presence of esp, purK1, and
ampicillin resistance were most frequent among outbreak-
associated isolates and almost absent among community
surveillance isolates. Vancomycin-resistance was not
specifically linked to genogroups. VREF and VSEF from
different epidemiologic sources are genetically related; evi-
dence exists for nosocomial selection of a subtype of E.
faecium, which has acquired vancomycin-resistance
through horizontal transfer. 
E
nterococcus faecium has become an important
nosocomial pathogen, especially in immuno-
compromised patients, creating serious limitations in
treatment options because of cumulative resistance to
antimicrobial agents (1). In the United States, the
emergence of nosocomial E. faecium infections was
characterized by increasing resistance to ampicillin in the
1980s and a rapid increase of vancomycin resistance in the
next decade (1,2). The emergence of vancomycin-resistant
E. faecium (VREF) in the United States illustrates the
transmission capacities of bacteria and the possibility of a
postantibiotic era for nosocomial infections in critically ill
patients. 
The global epidemiology of VREF is not well under-
stood. In the United States, prevalences of colonization
and infection are high among hospitalized patients, but a
community reservoir of VREF in healthy persons or ani-
mals seems to be absent (3,4). In contrast, in Europe, col-
onization and infection rates within hospitals remain low,
although colonization among healthy persons and animals
is prevalent (5–10). 
Previous studies suggested host-specificity of VREF
genogroups (11), and isolates associated with nosocomial
outbreaks seemed to be genetically distinct from nonepi-
demic VREF isolated from humans and animals (12). The
differences between epidemic and nonepidemic isolates
were based on genetic relatedness, as determined by
amplified fragment length polymorphism analysis (AFLP),
and the presence of an identical sequence of the purK
housekeeping gene in epidemic strains (12). A recently
developed multilocus sequence typing scheme for E. faeci-
um confirmed that epidemic isolates belonged to a specif-
ic genetic lineage (13). Moreover, a variant of the esp
gene, which has been found to be more prevalent among
isolates of E. faecalis associated with infections (14), was
found in all but one epidemic hospital-derived VREF iso-
late and not among community-derived VREF (12).
Subsequently, other investigators described the variant esp
gene in vancomycin-susceptible E. faecium (VSEF), and
this gene appeared to be predominantly present among
clinical isolates (15–18).These findings suggest the exis-
tence of a specific subpopulation of E. faecium, compris-
ing both VREF as well as VSEF, associated with hospital
outbreaks and infections. 
In this study, we further investigated the genetic rela-
tionship between VREF and VSEF isolates, derived from
different epidemiologic sources, such as hospital out-
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patients and healthy persons. The genetic relatedness was
linked to the presence of the variant esp gene and antibiot-
ic resistance to ampicillin and vancomycin. On the basis of
our findings, we constructed an evolutionary scheme
describing the sequential steps in the development and
selection of ampicillin- and vancomycin-resistant E. faeci-
um strains.
Materials and Methods
Bacterial Strains and Growth Conditions 
Isolates of VREF (n=108) were collected from nosoco-
mial epidemics (n=16), clinical infections (n=20), clinical
surveys (n=36), and community surveys (n=36) (Table 1).
The genotypes of these isolates have been described previ-
ously (11,12). Strains were considered epidemic if they
were isolated from patients treated in the same hospital, in
the same ward and with an overlapping time-relationship,
and if AFLP patterns showed at least 90% similarity (12).
Epidemic isolates were recovered from clinical sites, blood
and urine, as well as from feces. Only one representative
isolate from each outbreak was used for analysis. The
number of patients involved in each outbreak varied from
4 to >50 (12,19–23). Isolates were considered to be
derived from a clinical infection if obtained from a clinical
specimen, such as the blood, urine, and wounds. All sur-
veillance isolates, from patients and healthy persons, were
isolated from fecal samples. Surveillance isolates were
either from the community or from clinical surveillance
when obtained from hospitalized patients. The hospital-
stay duration of these patients, when cultures were
obtained, was not available.
Isolates of VSEF (n=92) were derived from clinical
infections (n=73), clinical surveys (n=5), and community
surveys (n=14). The isolates from clinical infectious sites
were obtained from the SENTRY Antimicrobial
Surveillance Program, and originated from different hospi-
tals in several European countries (Portugal, Germany,
United Kingdom, France, Spain, Italy, Austria, Turkey,
Switzerland, Greece, and Poland). Fifty-seven strains were
blood isolates, 5 were isolated from urine, 8 from wounds,
and 2 from respiratory tract specimens. Patient information
was not available. All VSEF isolates derived from clinical
surveys of fecal samples were from the University
Hospital Maastricht. All VSEF isolates from community
surveys of fecal samples were collected in the Netherlands.
All bacterial isolates were collected during the 1990s.
Identification and Susceptibility Testing
Enterococci were identified to the species level and
were tested for the presence of the vanA gene by using a
multiplex PCR described by Dutka-Malen et al. (24).
Vancomycin and ampicillin/amoxicillin susceptibilities
were determined by standard agar dilution methods,
according to the National Committee for Clinical
Laboratory Standards (NCCLS) guidelines (25). We con-
sidered MICs >16 µg/mL for ampicillin or amoxicillin and
>8 for vancomycin to be resistant.
Esp PCR
All strains were screened for esp by PCR, with two dif-
ferent primer sets (esp 11 [5′-TTGCTAATGCTAGTC-
CACGACC-3′] to esp 12 [5′-GCGTCAACACTTG-
CATTGCCGAA-3′] and 14F [5′-AGATTTCATCTTT
GATTCTTGG-3′] to 12R [5′-AATTGATTCTTTAGC
ATCTGG-3′]). PCR conditions included an initial denatu-
ration at 95°C for 15 min for activation of the HotStarTaq
DNA polymerase (QIAGEN GmbH, Hilden, Germany),
followed by 30 cycles of 94°C for 30 sec, 52°C for 30 sec,
and 72°C for 1 min, followed by an extension at 72°C for
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Table 1. Description of studied Enterococcus faecium isolates 
Origin  Country  n 
Vancomycin-resistant E. faecium 
United Kingdom  1 
Netherlands  4 
Epidemic 
United States  11 
Austria  1 
United Kingdom  7 
Israel  2 
Italy  1 
Netherlands  8 
Clinical infections 
United States  1 
Germany  1 
France  4 
United Kingdom  1 
Israel  1 
Italy  1 
Netherlands  27 
Clinical surveillance 
Slovenia  1 
United Kingdom  1  Community surveillance 
Netherlands  35 
Vancomycin-susceptible E. faecium 
Austria  6 
Belgium  1 
Switzerland  3 
Germany  14 
Spain  8 
France  8 
United Kingdom  1 
Greece  1 
Italy  16 
Poland  5 
Portugal  5 
Clinical infections 
Turkey  5 
Clinical surveillance  Netherlands  5 
Community surveillance  Netherlands  14 7 min. Reactions were performed in 25 µL by using the
HotStarTaq Master Mix (QIAGEN GmbH). Strains nega-
tive in PCR were checked for the presence of the esp gene
by Southern hybridization, as described previously (12).
For this check, we generated an esp-specific probe (956 bp)
using primers esp 11 and esp 12 (see previous explanation).
Sequencing PurK
The purK gene encodes a phosphoribosylaminoimida-
zole carboxylase ATPase subunit involved in purine
biosynthesis and is one of the seven housekeeping genes
selected for multilocus sequence typing of E. faecium (13).
A 492-bp fragment of the purK gene of a selection of
strains, divided over all genogroups, was sequenced by
using primers 5′-GCAGATTGGCACATTGAAAGT-3′
and 5′-TACATAAATCCCGCCTGTTTC/T-3′. PCR condi-
tions included an initial denaturation at 95°C for 3 min,
followed by 35 cycles of 94°C for 30 sec, 50°C for 30 sec,
and 72°C for 30 sec, followed by an extension at 72°C for
5 min. Reactions were performed in 50 µLby using buffers
and Taq polymerase (SphaeroQ, Leiden, Netherlands). The
PCR products were purified with a PCR purification kit
(QIAGEN GmbH) according to the manufacturer’s
instructions. Subsequently, purified PCR products were
sequenced directly with the ABI PRISM Big Dye
Terminators cycle sequencing kit on an ABI PRISM DNA
analyzer (Applied Biosystems, Foster City, CA).
Sequences were aligned with BioNumerics (v. 2.5, Applied
Maths, Kortrijk, Belgium) software.
AFLP
AFLP typing and computer analysis of AFLP-generat-
ed patterns of VSEF was done as described previously (11)
with minor modifications. Briefly, chromosomal DNAwas
digested with CfoI and EcoRI and ligated to a single
adapter with CfoI and EcoRI protruding ends in a simulta-
neous reaction, followed by PCR using adapter-specific
primers. The amplification products were separated and
detected by using POP6-polymer on an ABI PRISM3700
DNAAnalyzer (Applied Biosystems). For each sample, 1
µL of the PCR reaction mixture (8 x diluted) was added to
9 µL of Hi-Di Formamid containing 12.5 µL/mL of the
internal size marker (GeneScan-500–labeled with the red
fluorescent dye 6-carboxy-x-rhodamine) in a MicroAmp
Optical 96-well reaction plate (Applied Biosystems). The
analyses were run in 3 hours. Genescan software (Applied
Biosystems) was used for collection of data during the
analysis and the data were subsequently exported into
BioNumerics (Applied Maths) for further analysis. The
Pearson product moment correlation coefficient was calcu-
lated, and the unweighted pair group method with arith-
metic averages was used for cluster analysis. Using this
methodology, we described four genogroups of VREF
(11). We analyzed all isolates of VSEF and defined a clus-
ter of isolates as a set of individual strains with AFLP pat-
terns that shared at least 65% of the banding patterns (cri-
terion defined for four genogroups [11]). Subsequently, to
determine the matching genogroup, we compared AFLP
banding patterns of each individual VSEF isolate with
AFLP banding patterns of a library of 404 VREF, repre-
senting the four different AFLP genogroups. The library
included VREF recovered from pigs (n=108) and nonhos-
pitalized persons (n=28) as representatives of genogroup
A, and strains from poultry (n=32), hospitalized patients
(n=196), and calves (n=40), representing genogroups B, C,
and D, respectively (11,12).
VSEF isolates were identified by using the identifica-
tion module in BioNumerics. The genetic distance used for
further analysis is 100 minus the calculated Pearson prod-
uct moment correlation similarity coefficient. The degree
of matching was expressed by an identification factor,
which is the quotient of the average genetic distance
between the tested strain and each of the isolates in the
genogroup divided by the average genetic distance within
a genogroup. If the average distance of the tested strain to
each of the genogroup members is almost equal to the
average distance among all strains in a genogroup, the
identification factor will approach the value of one. So the
lower the value of the identification factor, the more likely
the test strain belongs to a particular genogroup.
Results
Using our predefined cutoff points for cluster analysis,
we identified four clusters of VSEF (Figure 1). VSEF clus-
tering seemed to be source-related. Clusters 1 (n=4) and 2
(n=12) contained surveillance isolates from community
sources predominantly. All but one of the clinical infec-
tions isolates belonged to clusters 3 (n=66) and 4 (n=10),
respectively.
On the basis of our calculations of the identification
factors of VSEF and representative isolates of different
VREF genogroups, we found that isolates of cluster 1
(n=4) resembled those of genogroup A, previously allocat-
ed to nonhospitalized patients and pig-derived VREF
(Table 2). Similarly, isolates of cluster 2 (n=12) fitted best
in genogroup B. Isolates from cluster 3 (n=66) showed
almost equal resemblance to isolates from genogroups B
and C, and isolates from cluster 4 (n=10) were also most
identical to isolates from genogroup C (Table 2). The rela-
tionship between AFLP clusters of VSEF and sources was
congruent with the previously described clustering of
VREF. Almost all VSEF isolates (99%) derived from clin-
ical infections clustered in clusters 3 and 4, clearly distinct
from most VSEF isolates from community surveys (93%),
which were found in clusters 1 and 2. Asimilar distribution
was found previously among VREF with most (60%) iso-
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(89%) isolates from community surveys in genogroup A
(11).
The presence of the variant esp gene in VREF and
VSEF was strongly associated with a specific epidemio-
logic source because the presence of esp is higher in clini-
cal infections and epidemic-associated isolates than in sur-
veillance isolates (Figure 2). VREF isolates associated
with nosocomial outbreaks were esp-positive, except for
one. Prevalences of the variant esp gene in clinical infec-
tious isolates were 57% and 40% for VSEF and VREF,
respectively (p=ns). Prevalence of the variant esp gene in
clinical and community survey isolates was low among
VREF (6% and 3%, respectively) and completely absent
among the 19 VSEF isolates tested. 
Associations similar to the variant esp gene were found
between ampicillin resistance and epidemiologic source
for enterococcal isolates (Figure 2). All isolated associated
with nosocomial VREF-outbreaks but one were resistant to
ampicillin, as were 81% and 65% of infectious isolates of
VSEF and VREF, respectively. Thirty-one percent of 36
nosocomial surveillance isolates of VREF were ampicillin
resistant, as compared to none of five VSEF isolates
obtained by clinical surveillance (p=ns). Finally, all but
one isolate of VREF (n=36) and all VSEF isolates (n=14)
obtained by surveillance of healthy persons were suscepti-
ble to ampicillin. When we combined these data, we found
strong associations between the presence of the variant
esp-gene and ampicillin resistance, both in VREF and
VSEF: 98% of esp-positive VSEF and 92% of esp-positive
VREF were resistant to ampicillin, as compared to 37%
esp-negative VSEF and 20% esp-negative VREF isolates
(p<0.0001).
The purK housekeeping gene was sequenced in 103
isolates: 64 VREF and 39 VSEF. The previously described
type 1 allele was found in 39 isolates: 23 VREF and 16
VSEF. This specific allele type was associated with the
presence of the variant esp-gene and ampicillin resistance
but not with vancomycin resistance. The variant esp-gene
was found in 25 (64%) of 39 isolates containing the purK
type 1 allele and in only 1 (2%) of 64 isolates carrying
other purK alleles (p<0.0001). Similarly, ampicillin resist-
ance was detected in 36 (92%) of 39 isolates with purK
type 1 allele and in only 5 (8%) of 64 isolates with other
allele types (p<0.0001). In contrast, the vanA transposon
was present in 23 (59%) of 39 isolates with purK type 1
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Table 2. Mean identification factor calculated for 92 vancomycin-susceptible Enterococcus faecium (VSEF) in clusters 1, 2, 3, and 4 
to the vancomycin-resistant E. faecium (VREF) genogroups A–D 
Genogroup A  Genogroup B  Genogroup C  Genogroup D 
Cluster  n  IF
a  IF  IF  IF 
1  4  1.48± ±0.06  1.76±0.16  2.5±0.16  3.93±0.31 
2  12  2.25±0.20  1.53± ±0.10  2.12±0.15  3.33±0.16 
3  66  2.98±0.10  1.58± ±0.07  1.72± ±0.09  3.97±0.06 
4  10  3.91±0.45  2.36±0.29  1.39± ±0.05  4.74±0.32 
aThe mean identification factor (IF) represents a measure of how well the entries of the four different VSEF clusters belong to one of the previously described VREF 
genogroups, taking into consideration the internal spread of the VREF genogroups. Mean identification factor was determined by calculating the arithmetic averages of 
identification factors of isolates of a given cluster. The lowest identification factor (indicated in boldface type) represents the highest probability that isolates in a given 
VSEF cluster belong to a certain VREF genogroup. The 95% confidence limits are shown for each identification factor. 
Figure 1. Cluster analysis of vancomycin-susceptible
Enterococcus faecium (VSEF) isolates originating from clinical
infections and clinical and community surveys. VSEF (n=92) were
genotyped by amplified fragment length polymorphism (AFLP).
Grouping of AFLP patterns showed four different clusters with
>65% similarity. Numbers on the horizontal axis indicate percent-
age similarity. Closed circles indicate presence of the esp gene
and the purK-1 allele and also the source of the isolates. Open cir-
cles represent esp-negative strains and other purK alleles. Closed
arrowheads indicate ampicillin resistance. The vertical dashed line
indicates the level of 65% similarity. Horizontal dashed lines indi-
cate the boundaries of the four different clusters.allele and in 41 (64%) of 64 isolates with other allele types
(p=ns).
Discussion
Our study demonstrates the genetic relatedness of clus-
ters of isolates of vancomycin-resistant and -susceptible E.
faecium strains from different epidemiologic sources and
provides evidence for selection of an E. faecium subtype
associated with hospital outbreaks. This subtype is charac-
terized by the presence of both ampicillin resistance and
the variant esp gene. Furthermore, our findings suggest
random horizontal spread of the vanA transposon to multi-
ple genogroups of E. faecium. We hypothesize that the rise
in infections caused by VREF resulted from nosocomial
selection of a specific ampicillin-resistant E. faecium
genotype harboring the variant esp gene and subsequent
horizontal transfer of the vanA transposon. 
Our study confirms that the previously demonstrated
dichotomy between VREF isolated from healthy persons
and patients (11) also exists for vancomcyin-susceptible E.
faecium isolates. In VREF isolates, we could identify four
genogroups, which were associated with particular hosts
and environments and in which most isolates from healthy
persons clustered distinctly from patient isolates. We
showed that vancomycin-susceptible isolates clustered
into three of these groups and that VSEF isolates from
healthy persons also clustered distinctly from patient iso-
lates. The genetic relationship between isolates and the
genetic distinction between the four genogroups were
based on AFLPanalysis. We recently confirmed these find-
ings with multilocus sequence typing (MLST) (13). Other
researchers have also demonstrated host specificity of E.
faecium. Quednau et al. suggested host specificity of iso-
lates from chicken, pork, and humans by comparing
restriction endonuclease profiles (26). In contrast, a recent
study by Vancanneyt et al. also used AFLP; they did not
confirm host-specific clustering of E. faecium (27). They
described two main genomic groups in a population of 78
E. faecium strains isolated from seven European countries,
and both groups comprised strains from (healthy) humans,
animals, and food. All human clinical strains clustered in
the largest genogroup, as did all strains (n=16) containing
the vanA gene. Our findings that the vanA transposon was
present in isolates of all genogroups proves that acquisition
of this transposon was not influenced by and did not affect
the preexisting relationship between the bacterium and
host, which is a result of a long-term coevolution and
mutual adaptation.
The presence of four genogroups in E. faecium seems
to parallel the phylogenetic structure in E. coli, in which
four ancestral groups (A, B1, B2, and D) have been
described with some level of host specificity (28).
However, in contrast to our finding of a single genetic lin-
eage in E. faecium related to clinical symptoms and carry-
ing the esp virulence gene, clinical isolates of E. coli are
more widely distributed among the different ancestral
groups (29). Furthermore, MLST of pathogenic E. coli
strains showed that different ancestral lineages have
acquired the same virulence factors (30), indicating that
pathogenic potential in E. coli is not confined to a single
ancestral lineage, which is suggested by our findings for E.
faecium. Human and animal pathogenic E. coli strains
share closely related genotypes and carry similar virulence
factor profiles, suggesting that certain E. coli strains are
pathogenic for both animals and humans (31). Whether
this holds true for pathogenic E. faecium strains is
unknown.
We recently found that the presence of the variant esp-
gene is associated with nosocomial outbreaks of VREF in
three continents, although this gene was not found in
VREF strains isolated from healthy persons or animals
(12). The outbreak strains were also characterized by a
specific allele type of the purK gene, one of the house-
keeping genes sequenced in the MLST method (13).
Recently, other investigators reported the presence of the
variant esp gene in clinical isolates of VSEF, demonstrat-
ing that this gene is not linked specifically to the vanA
transposon (15–18). The findings of our study confirm the
strong association between the presence of the esp gene
and the relation with hospital outbreaks and clinical infec-
tions among patients with VREF as well as VSEF.
Although the esp gene is virtually absent among commu-
nity isolates, the presence of esp among VSEF and VREF
from clinical infectious sites apparently unrelated to hospi-
tal outbreaks implies that this gene is not exclusively relat-
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Figure 2. Frequencies of the esp gene and ampicillin resistance
among vancomycin-susceptible enterococci (VSE) and van-
comycin-resistant enterococci (VRE) of different origin.
Percentages of esp-positive (solid bars) and ampicillin-resistant
(dotted bars) VRE and VSE isolates originating from four different
sources have been indicated. Clin-Inf, clinical infectious; Clin-Surv,
clinical survey; Comm-Surv, community survey.ed to epidemic strains. Excluding the outbreak potential of
the esp-positive VSEF strains in this and other studies is
difficult. Only few outbreaks with VSEF have been docu-
mented (32–34). We have investigated and could not
demonstrate the presence of the variant esp gene in isolates
from one hospital outbreak of ampicillin-resistant E. faeci-
um in Norway (data not shown). 
Little is known about the function of the variant esp-
gene, although epidemiologic findings support its role as a
virulence factor. In E. faecalis, the homologue of this gene
encodes for the enterococcal surface protein, and the pres-
ence of this gene has been associated with enhanced adher-
ence capacities to uroepithelial surfaces, but not with
increased virulence, in a mice model (35). Moreover, in E.
faecalis, the esp-gene was highly associated with biofilm-
formation capacity (36). Increased adherence capacities
and biofilm formation of esp-positive E. faecium strains
might explain its association with hospital outbreaks. 
Like the variant esp gene, ampicillin resistance was
found more frequently in isolates associated with infec-
tions and nosocomial outbreaks, both in VSEF and VREF.
This source-relationship is probably caused by selective
pressure of β-lactam antibiotics that are used extensively
in hospitals. Emergence of ampicillin resistance in E. fae-
cium was already demonstrated in the early 1980s and
seemed to precede the emergence of vancomycin resist-
ance by 10 years (2). A correlation between high preva-
lences of the esp gene and antibiotic resistance among E.
faecium isolates from hospitalized patients was also
reported recently by Coque et al. (17).
Considering the sources of isolates, presence of ampi-
cillin and vancomycin resistance, the presence of the vari-
ant esp gene, and the type 1 allele of the purK gene, we
propose an evolutionary scheme for the specific
genogroup of E. faecium associated with nosocomial out-
breaks (Figure 3). However, our findings might have been
biased by the composition of our collection of isolates and
the fact that the purK was sequenced in a subset of all iso-
lates. The esp gene and ampicillin resistance can obvious-
ly co-occur in a distinct genetic lineage of E. faecium char-
acterized by the type 1 allele of the purK gene. We propose
that E. faecium strains containing the type 1 allele of the
purK gene have acquired the esp virulence gene and that
this E. faecium genotype (purK-1, esp-positive) is promi-
nently present among clinical relevant strains and virtually
absent among survey isolates. Yet another substantial part
of the clinical relevant strains with genotype purK-1 do not
carry the esp gene, which emphasizes that other virulence
genes of E. faecium apart from esp are involved in the
development of infections. Ampicillin resistance was pre-
dominantly found among the purK-1 genotype and is
almost absent among other E. faecium genotypes. This
occurrence of resistance is, presumably, the result of selec-
tive antibiotic pressure. Chromosomal linkage of the purK-
1 allele, the variant esp gene, and ampicillin resistance
could have promoted this selection. Finally, glycopeptide
usage in and outside hospitals, both in humans and ani-
mals, resulted in the selection of vancomycin-resistant
strains in both the purK-1 genotype and the other geno-
types. The presence of similar proportions of vancomycin
resistance in all genotypes probably reflects horizontal
transfer of the vancomycin-resistance transposon. This
hypothesis implies the development of a hospital-adapted
genogroup of E. faecium, characterized by the type-1 allele
of purK, the variant esp-gene, and ampicillin resistance,
which has spread unnoticed, thereby creating a pool of
strains with epidemic potential. Only after becoming van-
comycin-resistant has this genogroup become recognized
as clinically relevant.
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Figure 3. Hypothetical evolutionary scheme for Enterococcus fae-
cium genotypes and phenotypes from an ancestral E. faecium
type. Open slices indicate esp-negative, ampicillin-susceptible,
and vancomycin-susceptible. Closed slices indicate esp-positive,
ampicillin-resistant, and vancomycin-resistant. Numbers indicate
the number of strains. Arrows indicate the putative evolutionary
direction. Clin-Inf, clinical infectious; Clin-Surv, clinical survey;
Comm-Surv, community survey. 
a, dominant genogroup (A,C) for
vancomycin-resistant enterococci and dominant cluster (2,3,4) for
vancomycin-susceptible enterococci. 
b, clinical relevant strains
(“yes”) are the total of epidemic and clinical infectious isolates,
clinical nonrelevant strains (“no”) are the total of clinical and com-
munity survey isolates.demiology of vancomycin-resistant enterococci and enterococcal
pathogenicity mechanisms.
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